Antimicrobial resistance in the next 30 years, humankind, bugs and drugs: a visionary approach
- 3.9k Downloads
To describe the current standards of care and major recent advances with regard to antimicrobial resistance (AMR) and to give a prospective overview for the next 30 years in this field.
Review of medical literature and expert opinion were used in the development of this review.
There is undoubtedly a large clinical and public health burden associated with AMR in ICU, but it is challenging to quantify the associated excess morbidity and mortality. In the last decade, antibiotic stewardship and infection prevention and control have been unable to prevent the rapid spread of resistant Gram-negative bacteria (GNB), in particular carbapenem-resistant Pseudomonas aeruginosa (and other non-fermenting GNB), extended-spectrum β-lactamase (ESBL)-producing and carbapenem-resistant Enterobacteriaceae (CRE). The situation appears more optimistic currently for Gram-positive, where Staphylococcus aureus, and particularly methicillin-resistant S. aureus (MRSA), remains a cardinal cause of healthcare-associated infections worldwide. Recent advancements in laboratory techniques allow for a rapid identification of the infecting pathogen and antibiotic susceptibility testing. Their impact can be particularly relevant in settings with prevalence of MDR, since they may guide fine-tuning of empirically selected regimen, facilitate de-escalation of unnecessary antimicrobials, and support infection control decisions.
Currently, antibiotics are the primary anti-infective solution for patients with known or suspected MDR bacteria in intensive care. Numerous incentives have been provided to encourage researchers to work on alternative strategies to reverse this trend and to provide a means to treat these pathogens. Although some promising antibiotics currently in phase 2 and 3 of development will soon be licensed and utilized in ICU, the continuous development of an alternative generation of compounds is extremely important. There are currently several promising avenues available to fight antibiotic resistance, such as faecal microbiota, and phage therapy.
KeywordsAntimicrobial resistance Antibiotics Diagnostic test Microbiota Phage therapy Vaccine
Antibiotic susceptibility testing
Health-care associated infections
Intensive care unit
Methicillin-resistant Staphylococcus aureus
Infection prevention and control
Vancomycin-intermediate Staphylococcus aureus
Whole genome sequencing
Compliance with ethical standards
Conflicts of interest
MB serves on scientific advisory boards for AstraZeneca, Bayer, Cubist, Pfizer Inc, MSD, Tetraphase and Astellas Pharma Inc.; has received funding for travel or speaker honoraria from Algorithm, Angelini, Astellas Pharma Inc., AstraZeneca, Cubist, Pfizer MSD, Gilead Sciences, Novartis, Ranbaxy, Teva. ER serves on the scientific board of MaaT Pharma, and is consultant for DaVolterra. AB serves on advisory board for MSD and Takeda pharmaceuticals and speaker’s bureau for Pfizer, MSD and Sanofi-aventis. The other authors declare that they have no conflict of interest.
- 5.Lee BY, Bartsch SM, Wong KF et al (2016) The potential trajectory of carbapenem-resistant Enterobacteriaceae, an emerging threat to health-care facilities, and the impact of the centers for disease control and prevention toolkit. Am J Epidemiol 183(5):471–479CrossRefPubMedPubMedCentralGoogle Scholar
- 7.Kanamori H, Parobek CM, Juliano JJ et al (2017) A prolonged outbreak of KPC-3-producing Enterobacter cloacae and Klebsiella pneumoniae driven by multiple mechanisms of resistance transmission at a large academic burn center. Antimicrob Agents Chemother 61(2):e01516-16. doi: 10.1128/AAC.01516-1
- 9.Newitt S, Myles PR, Birkin JA et al (2015) Impact of infection control interventions on rates of Staphylococcus aureus bacteraemia in National Health Service acute hospitals, East Midlands, UK, using interrupted time-series analysis. J Hosp Infect 90:28–37. doi: 10.1016/j.jhin.2014.12.016 CrossRefPubMedGoogle Scholar
- 11.Andrey DO, François P, Manzano C et al (2017) Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2013–2014 at the Geneva University Hospitals. Eur J Clin Microbiol Infect Dis 36:343–350. doi: 10.1007/s10096-016-2807-5 CrossRefPubMedGoogle Scholar
- 30.Cambau E, Durand-Zaleski I, Bretagne S et al (2017) Performance and economic evaluation of the molecular detection of pathogens for patients with severe infections: the EVAMICA open-label, cluster-randomised, interventional crossover trial. Intensive Care Med. doi: 10.1007/s00134-017-4766-4 PubMedGoogle Scholar
- 32.Montuschi P, Mores N, Trove A et al (2013) The electronic nose in respiratory medicine. Respir Int Rev Thorac Dis 85(1):72e84Google Scholar
- 41.Bhalla A, Pultz NJ, Ray AJ et al (2003) Antianaerobic antibiotic therapy promotes overgrowth of antibiotic-resistant, Gram-negative bacilli and vancomycin-resistant enterococci in the stool of colonized patients. Infect Control Hosp Epidemiol 24:644–649. doi: 10.1086/502267 CrossRefPubMedGoogle Scholar
- 42.Bernard J, Armand-Lefèvre L, Luce E et al (2016) Impact of a short exposure to levofloxacin on faecal densities and relative abundance of total and quinolone-resistant Enterobacteriaceae. Clin Microbiol Infect 22(7):646.e1–4. doi: 10.1016/j.cmi.2016.04.015
- 43.Ruppé E, Lixandru B, Cojocaru R et al (2013) Relative fecal abundance of extended-spectrum-β-lactamase-producing Escherichia coli strains and their occurrence in urinary tract infections in women. Antimicrob Agents Chemother 57:4512–4517. doi: 10.1128/AAC.00238-13 CrossRefPubMedPubMedCentralGoogle Scholar
- 44.Woerther P-L, Micol J-B, Angebault C et al (2015) Monitoring antibiotic-resistant enterobacteria faecal levels is helpful in predicting antibiotic susceptibility of bacteraemia isolates in patients with haematological malignancies. J Med Microbiol 64:676–681. doi: 10.1099/jmm.0.000078 CrossRefPubMedGoogle Scholar
- 51.Stool transplantation to reduce antibiotic resistance transmission. https://clinicaltrials.gov/ct2/show/NCT02461199. Accessed 10 July 2017
- 52.Fecal transplant for MDR pathogen decolonization. https://clinicaltrials.gov/ct2/show/NCT02906774. Accessed 10 July 2017
- 53.FMT for multidrug resistant organism reversal. https://clinicaltrials.gov/ct2/show/NCT02312986. Accessed 10 July 2017
- 54.Biotherapy for MRSA enterocolitis. https://clinicaltrials.gov/ct2/show/NCT02390622. Accessed 10 July 2017
- 55.FMT for MDRO colonization after infection in renal transplant recipients. https://clinicaltrials.gov/ct2/show/NCT02922816. Accessed 10 July 2017
- 58.Buffie CG, Bucci V, Stein RR et al (2015) Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517:205–208. doi: 10.1038/nature13828
- 61.Wright A, Hawkins CH, Anggård EE et al (2009) A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 34:349–357. doi: 10.1111/j.1749-4486.2009.01973.x CrossRefPubMedGoogle Scholar
- 63.Standard treatment associated with phage therapy versus placebo for diabetic foot ulcers infected by S. aureus. https://clinicaltrials.gov/ct2/show/NCT02664740. Accessed 10 July 2017
- 64.Evaluation of phage therapy for the treatment of Escherichia coli and Pseudomonas aeruginosa wound infections in burned patients. https://clinicaltrials.gov/ct2/show/NCT02116010. Accessed 10 July 2017
- 76.Cdiffense: Clostridium difficile vaccine trial. http://www.cdiffense.org/. Accessed 10 July 2017
- 79.AMR Review. https://amr-review.org/Publications. Accessed 23 Jan 2017